Stocks News

LAST PRICE
173.0400
TODAY'S CHANGE (%)
Trending Down-0.8800 (-0.5060%)

Bid / Lots
172.2100/ 1
Ask / Lots
174.0000/ 1
Open / Previous Close
173.5800 / 173.9200
Day Range
Low 171.5700
High 175.2000
52 Week Range
Low 170.7100
High 268.2950
Volume
1,581,739
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 5, 2024
- Argus Cuts Biogen's Price Target to $200 From $250, from 2:14PM ET on Tuesday Nov 05, 2024 by MT Newswires
  2:14PM ET on Tuesday Nov 05, 2024 by MT Newswires
  Companies Mentioned: BIIB
  02:14 PM EST, 11/05/2024 (MT Newswires) -- Biogen (BIIB) has an average rating of outperform and price targets ranging from $180 to $342, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from m...
Nov 4, 2024
- DJ Biogen Is Maintained at Neutral by JP Morgan, from 9:47AM ET on Monday Nov 04, 2024 by Dow Jones
  9:47AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: BIIB
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/BIIB/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 04, 2024 09:47 ET (14:47 GMT)
Nov 1, 2024
- Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA, from 8:13AM ET on Friday Nov 01, 2024 by MT Newswires
  8:13AM ET on Friday Nov 01, 2024 by MT Newswires
  Companies Mentioned: BIIB
  08:13 AM EDT, 11/01/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said late Thursday that Eisai finalized a biologics license application rolling submission to the FDA for a subcutaneous autoinjector of LEQEMBI, or lecanemab-irmb, for weekly dosing...
Oct 31, 2024
- DJ Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com, from 5:31PM ET on Thursday Oct 31, 2024 by Dow Jones
  5:31PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: LLY, RHHBY, BIIB
  
  By Bill Alpert
  
  Roche Holding has one of the most promising treatments for Alzheimer's in clinical trials. The drug is several years away from reaching the market, however.
- DJ Biogen Is Maintained at Outperform by Oppenheimer, from 2:19PM ET on Thursday Oct 31, 2024 by Dow Jones
  2:19PM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: BIIB
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/BIIB/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 14:19 ET (18:19 GMT)

Yesterday
- S&P 500 Closes Just Shy of Record 6,000 Amid Strong Post-Election Rally, from 17 hours ago by MT Newswires
  17 hours ago by MT Newswires
  Companies Mentioned: HD, CSCO, SPGI, VTRS, TSLA, WBD, MRNA, AZN, PLTR, CE, DIS, MTCH
- BioNTech Shares Rise After Goldman Sachs Upgrade, from 19 hours ago by MT Newswires
  19 hours ago by MT Newswires
  Companies Mentioned: BNTX
- DJ Moderna Is Maintained at Overweight by Barclays, from 20 hours ago by Dow Jones
  20 hours ago by Dow Jones
  Companies Mentioned: MRNA
- Jefferies Adjusts Moderna Price Target to $50 From $55, from 21 hours ago by MT Newswires
  21 hours ago by MT Newswires
  Companies Mentioned: MRNA
- Goldman Sachs Adjusts Moderna Price Target to $112 From $130, from 21 hours ago by MT Newswires
  21 hours ago by MT Newswires
  Companies Mentioned: MRNA
- Leerink Partners Adjusts Moderna Price Target to $38 From $46, from 21 hours ago by MT Newswires
  21 hours ago by MT Newswires
  Companies Mentioned: MRNA
- Barclays Adjusts Moderna Price Target to $111 From $125, from 21 hours ago by MT Newswires
  21 hours ago by MT Newswires
  Companies Mentioned: MRNA
- European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading, from 22 hours ago by MT Newswires
  22 hours ago by MT Newswires
  Companies Mentioned: PHG, PUK, IHG, SQNS, GRFS, AUTL, AKTX, MREO, BHP, TCBP, MTLS, DBVT, CUK
- BofA Securities Adjusts Price Target on Moderna to $90 From $110, Maintains Neutral Rating, from 23 hours ago by MT Newswires
  23 hours ago by MT Newswires
  Companies Mentioned: MRNA
- Moderna Says RSV Vaccine Approved by Health Canada for Older Adults, from 8:44AM ET on Friday Nov 08, 2024 by MT Newswires
  8:44AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: MRNA

Biogen Inc
NASDAQ:BIIBUnited States

Search Criteria

Nov 5, 2024

Argus Cuts Biogen's Price Target to $200 From $250, from 2:14PM ET on Tuesday Nov 05, 2024 by MT Newswires

Nov 4, 2024

DJ Biogen Is Maintained at Neutral by JP Morgan, from 9:47AM ET on Monday Nov 04, 2024 by Dow Jones

Nov 1, 2024

Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA, from 8:13AM ET on Friday Nov 01, 2024 by MT Newswires

Oct 31, 2024

DJ Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com, from 5:31PM ET on Thursday Oct 31, 2024 by Dow Jones

DJ Biogen Is Maintained at Outperform by Oppenheimer, from 2:19PM ET on Thursday Oct 31, 2024 by Dow Jones

Peers Headlines

Yesterday

S&P 500 Closes Just Shy of Record 6,000 Amid Strong Post-Election Rally, from 17 hours ago by MT Newswires

BioNTech Shares Rise After Goldman Sachs Upgrade, from 19 hours ago by MT Newswires

DJ Moderna Is Maintained at Overweight by Barclays, from 20 hours ago by Dow Jones

Jefferies Adjusts Moderna Price Target to $50 From $55, from 21 hours ago by MT Newswires

Goldman Sachs Adjusts Moderna Price Target to $112 From $130, from 21 hours ago by MT Newswires

Leerink Partners Adjusts Moderna Price Target to $38 From $46, from 21 hours ago by MT Newswires

Barclays Adjusts Moderna Price Target to $111 From $125, from 21 hours ago by MT Newswires

European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading, from 22 hours ago by MT Newswires

BofA Securities Adjusts Price Target on Moderna to $90 From $110, Maintains Neutral Rating, from 23 hours ago by MT Newswires

Moderna Says RSV Vaccine Approved by Health Canada for Older Adults, from 8:44AM ET on Friday Nov 08, 2024 by MT Newswires